E-resources
Peer reviewed
-
Mizugaki, Hidenori; Hamada, Akinobu; Shibata, Tatsuhiro; Hosoda, Fumie; Nakamura, Hiromi; Okuma, Yusuke; Shukuya, Takehito; Umemura, Shigeki; Horiike, Atsushi; Fukui, Tomoya; Kogure, Yoshihito; Daga, Haruko; Urata, Yoshiko; Yamada, Kazuhiko; Saeki, Sho; Fujisaka, Yasuhito; Nakamura, Yukiko; Sato, Mitsuo; Yoshida, Tatsuya; Hotta, Takamasa; Oizumi, Satoshi; Fujiwara, Yasuhiro; Ohe, Yuichiro; Fujiwara, Yutaka
Lung cancer (Amsterdam, Netherlands), February 2019, 2019-02-00, Volume: 128Journal Article
•We identified clinically significant AEs in 35% of 75 NSCLC patients.•We evaluated AEs and germline variations by target-gene panel sequencing.•These AEs were associated with nonsynonymous SNVs in EPHX1 and TCF7L2.•Germline multi-gene information might be useful for predicting AEs.•These strategies are helpful for better precision medicine in the clinic. Crizotinib is a standard treatment for advanced anaplastic lymphoma kinase (ALK)- or ROS1-fusion-gene-positive non-small cell lung cancer; however, serious adverse events (AEs), including elevated alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and interstitial lung disease (ILD), develop occasionally. Here, we evaluated relationships between clinically significant crizotinib-associated AEs and germline variations. DNA obtained from 75 patients allowed selection of 147 genes according to function, exon identification and sequencing, and determination of germline single nucleotide variants (SNVs). Correlations between clinically significant AEs and presence of germline variants were estimated by Fisher’s exact test. We defined clinically significant AEs as grade 4 hematological toxicity, grade ≥3 non-hematological toxicity, and any grade of ILD. These AEs were observed in 26 patients (35%), with elevated AST/ALT (15%) the most common, followed by neutropenia (5%), ILD (4%), and thromboembolic events (4%). Nonsynonymous SNVs in epoxide hydrolase 1 (EPHX1) odds ratio (OR): 3.86; p = 0.0009) and transcription factor 7-like 2 (TCF7L2) (OR: 2.51; p = 0.025) were associated with the presence of clinically significant AEs. Nonsynonymous EPHX1 and TCF7L2 SNVs might be associated with clinically significant crizotinib-associated AEs. These data indicated that target-gene sequencing could be feasible for predicting anticancer-agent toxicity, and that germline multi-gene information might be useful for predicting patient-specific AEs to promote precision medicine.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.